May 9th 2024
In an interview with Targeted Oncology, Shilpa Gupta, MD, discussed the rationale and potential significance of the MAIN-CAV trial in patients with locally advanced/metastatic urothelial carcinoma.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
BLA Submitted to the FDA for N-803 Plus BCG in BCG-Unresponsive Bladder Cancer
May 25th 2022A biologics license application has been submitted to the FDA for N-803 plus Bacillus Calmette-Guérin as treatment for patients with BCG-unresponsive non-muscle invasive bladder cancer in situ with or without Ta or T1 disease.
Read More
More Analyses Explore Benefit of Frontline Maintenance Avelumab Plus BSC in Advanced UC
May 19th 2022In an interview with Targeted Oncology, Joaquim Bellmunt, MD, PhD, discussed the long-term overall survival data for first-line maintenance avelumab in mUC presented at the AUA 2022 Annual Meeting and a sub-analysis of the JAVELIN Bladder 100 trial being read out at the upcoming 2022 ASCO Annual Meeting.
Read More
Mitomycin Gel Maintains QOL in Patients With Low Grade Non-Muscle Invasive Bladder Cancer
May 16th 2022Health-related quality-of-life outcomes were maintained among patients with low grade non-muscle invasive bladder cancer who were treated with UGN-102, a chemoablative reverse thermal gel as a primary approach in the single-arm phase 2b Optima II trial.
Read More
Infigratinib Demonstrates Activity and Tolerability of FGFR Inhibition in Urothelial Carcinoma
May 16th 2022Interim results from a biomarker-informed preoperative study of infigratinib demonstrated substantial activity and tolerability in patients with localized upper tract urothelial carcinoma, according to findings of a phase 1b trial.
Read More
Results of CG0070 Combined With Pembrolizumab in BCG-Unresponsive NMIBC
May 16th 2022Roger Li, MD, shares the results of the phase 2 CORE1 clinical trial, which evaluated CG0070 in combination with pembrolizumab for the treatment of patients with Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer.
Watch
Nintedanib With Neoadjuvant Chemotherapy Shows No PCR Benefit in MIBC
May 2nd 2022Nintedanib plus neoadjuvant chemotherapy did not achieve improvement in pathologic complete response in patients with muscle invasive bladder cancer in the phase 2 NEOBLADE study, but the study provided important survival signals.
Read More
Siefker-Radtke Discusses the Role of Antibody-Drug Conjugates in Urothelial Carcinoma
March 25th 2022During a Targeted Oncology case-based roundtable event, Arlene Siefker-Radtke discussed the second-line treatment options for a patient with urothelial carcinoma and the EV-301 trial of enfortumab vedotin.
Read More